Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

Recruiting now · Phase 2

Conditions studied: Hypopharyngeal Carcinoma

In brief

This is a multi-center, randomized controlled, prospective clinical study.

Key facts

Study ID

NCT07248956

Run by

Eye & ENT Hospital of Fudan University

People needed

116

Starts

2025-12-22

Expected to finish

2029-12-30

Last updated by the study team

2025-12-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willingness to provide written informed consent;
• Age ≥18 and ≤75 years;
• Treatment-naïve for malignant disease;
• Resectable stage III-IVA hypopharyngeal carcinoma with response of PR ≥ 50% after neoadjuvant therapy according to RECIST 1.1 ;
• ECOG performance status 0-2.

You may not qualify if…

• Pregnancy or breastfeeding status;
• Hypersensitivity to sintilimab, nab-paclitaxel, or their formulation components;
• Poorly controlled cardiovascular conditions or other diseases;
• Active or documented history of autoimmune diseases requiring systemic treatment;
• Synchronous or metachronous malignancies;
• Other conditions deemed ineligible for the study by investigators.

Where it is running

• Eye & ENT Hospital, Fudan University — Shanghai, China (enrolling)
• Shandong Provincial ENT Hospital — Jinan, Shandong, China
• Beijing Tongren Hospital, Capital Medical University — Beijing, China
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China
• Zhongshan Hospital of Fudan University — Shanghai, China
• Tianjin Medical University Cancer Institute & Hospital — Tianjin, China
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.